Objective. To elucidate the pathophysiologic links between prostaglandin E 2 (PGE 2 ) and osteoarthritis (OA) by characterizing the catabolic effects of PGE 2 and its unique receptors in human adult articular chondrocytes.
manner. PGE 2 titration combined with interleukin-1 (IL-1) synergistically accelerated expression of painassociated molecules such as inducible nitric oxide synthase and IL-6. Finally, stimulation with exogenous PGE 2 or an EP2 receptor-specific agonist inhibited activation of Akt that was induced by insulin-like growth factor 1.
Conclusion. PGE 2 exerts an antianabolic effect on human adult articular cartilage in vitro, and EP2 and EP4 receptor antagonists may represent effective therapeutic agents for the treatment of OA.
Osteoarthritis (OA) is a disabling disease that is highly prevalent in elderly patients (1) . It is a complex process involving a combination of cartilage degradation, repair, and inflammation, and its pathogenesis is not yet fully understood. Normal articular chondrocytes maintain a dynamic equilibrium between synthesis and degradation of extracellular matrix (ECM) components, which includes type II collagen fibrils surrounding and restraining large, hydrated aggregates of the proteoglycan aggrecan, allowing normal cartilage to function as a natural "shock absorber" and withstand compressive loads (2) . However, in OA, there is a disruption of the matrix equilibrium leading to progressive loss of cartilage tissue. Chondrocyte metabolism is unbalanced due to excessive production of catabolic factors, including matrix metalloproteinases (MMPs), aggrecanases (ADAMTS), and other cytokines and growth factors released by chondrocytes that aid in the destruction of proteoglycans and the ECM (3) (4) (5) (6) . Recently, synovial inflammation has been found to contribute to the pathogenesis of OA via the release of catabolic and proinflammatory mediators that alter matrix homeostasis (7) . Some studies have shown increased expression of proinflammatory proteins in human OA joint cartilage compared with normal cartilage (8) , and others have revealed a correlation between increased expression of inflammatory mediators and degradation of cartilage matrix macromolecules (9) .
Prostaglandins are proinflammatory lipid mediators that are locally increased in the synovial membrane and synovial fluid of patients with OA (8) . The role of prostaglandins in the metabolism of articular cartilage is still a matter of debate. Some reports indicate that prostaglandins participate in the destruction of articular cartilage by degrading cartilage ECM (10, 11) , while others show that they promote chondrogenesis and terminal differentiation (12, 13) . The opposing biologic roles attributed to these compounds is a direct reflection of the molecular complexity of prostaglandins and their unique cognate receptors (14) .
Prostaglandin E 2 (PGE 2 ) is one of the major catabolic mediators involved in cartilage degradation and the progression of OA (15) (16) (17) . PGE 2 is a prostanoid derived from arachidonic acid that is released from membranes by phospholipase A 2 . In the initial step in prostaglandin biosynthesis, arachidonic acid is metabolized by cyclooxygenase activity to form PGH 2 , which is subsequently metabolized by prostaglandin E synthase to form PGE 2 (18) . Previous studies have shown that PGE 2 is involved in inflammation, apoptosis, and angiogenesis (19, 20) . However, the precise biologic role of PGE 2 in articular cartilage is still unclear. PGE 2 has been associated with structural changes seen in OA tissues (21) and has been characterized as a catabolic mediator in cartilage homeostasis (10, (15) (16) (17) . In contrast, others have demonstrated an anabolic effect of PGE 2 in articular cartilage (22, 23) . The PGE 2 -mediated signal is transduced by 4 different EP receptor subtypes (EP1-EP4) that cause distinct and sometimes opposing effects on cell metabolism, depending on the cell/tissue types (23) , and at this point, it is not clear which of these EP receptor subtypes contribute to the pathogenesis of OA.
In this study, we demonstrated the pathophysiologic links between PGE 2 and OA. We also identified which specific EP receptors may be responsible for the biologic effect of PGE 2 in human articular cartilage, and we elucidated which of these receptors may contribute to the generation of OA symptoms via stimulation of nociceptive pathways in arthritic joints.
MATERIALS AND METHODS
Synovial fluid analysis. Human synovial fluid was aspirated within 24 hours of death from the knee joints of 9 asymptomatic human organ donors with no history of joint diseases (ages 45-60 years, with grade 0/1 degeneration) using approved institutional protocols (Gift of Hope Organ and Tissue Donor Network, Elmhurst, IL). Synovial fluid was also obtained with appropriate consent from 8 OA patients (ages 50-65 years, with advanced OA requiring surgery) and 18 patients with rheumatoid arthritis (RA) (ages 50-65 years) from the Rush University Section of Rheumatology who were undergoing diagnostic or therapeutic arthrocentesis. The level of PGE 2 was measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN) in standard curve units of pg/ml following the instructions provided by the manufacturer.
Chondrocyte isolation and culture. Human articular cartilage from knee or ankle was obtained from tissue donors through the Gift of Hope Organ and Tissue Donor Network. Each donor specimen was graded for gross degenerative changes based on a modified version of the 5-point scale of Collins (24) . The cells were released by enzymatic digestion as previously described (25, 26) . Alginate beads and monolayers were made for long-term and short-term analysis, respectively. For alginate bead culture, grade 0 or 1 knee chondrocytes were isolated and resuspended in 1.2% alginate, and beads were formed using a CaCl 2 solution, as previously described (27) . Cells were treated with PGE 2 (Sigma, St. Louis, MO), EP2 receptor-specific agonist (Butaprost; Cayman Chemical, Ann Arbor, MI), EP3 receptor-specific agonist (Sulprostone; Sigma), and interleukin-1 (IL-1; Amgen, Thousand Oaks, CA), a well-known catabolic cytokine used for control.
For monolayer culture, isolated chondrocytes were counted and plated onto 12-well plates at 8 ϫ 10 5 /cm 2 as previously described (5, 25) . Cells were treated with PGE 2 , basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1; Austral Biologicals, San Ramon, CA), EP2 receptor-specific agonist, EP3 receptor-specific agonist, EP1/2 antagonist AH6809 (Sigma), EP1 antagonist SC19220 (Sigma), EP4 antagonist AH23848 (Sigma), and IL-1. Cells were harvested at different time points and subjected to Western blotting as described below. Cells were treated for 24 hours before total RNA harvesting.
Real-time reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) following the instructions provided by the manufacturer. RT was carried out with 1 g total RNA using the ThermoScript RT-PCR system (Invitrogen) for first-strand complementary DNA (cDNA) synthesis. For real-time RT-PCR, cDNA was amplified using the MyiQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Relative messenger RNA (mRNA) expression was determined using the ⌬⌬C t method, as detailed by the manufacturer (Bio-Rad). GAPDH was used as internal control. The deviations in samples represent 3 different donors in 3 separate experiments. The primer sequences and their conditions for use are summarized in Table 1 .
Dimethylmethylene blue (DMMB) assay for proteoglycan production and DNA assay for cell numbers. On day 21 of culture, the alginate beads were collected and processed for proteoglycan assays using the DMMB assay, as previously described (27) . The proteoglycan levels measured in the cellassociated matrix were quantified per DNA to give the total amount of proteoglycans produced and retained in the alginate beads per cell (25) . Using PicoGreen (Molecular Probes, 514 LI ET AL Carlsbad, CA), cell numbers were determined by assay of total DNA in the cell pellets, as previously described (25) . 35 S-sulfate incorporation into newly synthesized proteoglycans. On day 7 of culture in alginate, the medium was removed and replaced by fresh medium. One hour later, this medium was replaced with fresh medium containing 35 Ssulfate at 20 Ci/ml (Amersham, Arlington Heights, IL). After 4 hours of incubation, the labeling medium was removed, and beads were rinsed and dissolved to separate out the cellassociated matrix and digested with papain (20 g/ml in 0.1M sodium acetate, 0.05M EDTA, pH 5.53). Sulfate incorporation into proteoglycans was measured using the Alcian blue precipitation method (28) . All samples were analyzed in duplicate and normalized for DNA content using Hoechst 33258 as previously described (28) .
Western blotting. Cell and tissue lysates were prepared using modified radioimmunoprecipitation assay buffer as previously described (6) . Protein was resolved by 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membrane for Western blot analyses as previously described (5) .
Statistical analysis. Analysis of variance was performed using StatView 5.0 software (SAS Institute, Cary, NC). P values less than 0.05 were considered significant.
RESULTS
PGE 2 is up-regulated in arthritic joints and suppresses proteoglycan in human articular chondrocytes via inhibition of aggrecan gene expression. Synovial fluid collected from knee joints of asymptomatic (normal) donors or from RA or OA patients was subjected to ELISA to assess endogenous levels of PGE 2 ( Figure 1A ). Compared with normal joints, the levels of PGE 2 were at least 2 times higher in patients with OA and RA, with a greater effect seen in OA synovial fluid, suggesting a pathologic role of PGE 2 in human knee joints.
To assess the biologic impact of PGE 2 on human articular cartilage, chondrocytes isolated from knee cartilage (grade 0/1) were encapsulated in 3-dimensional (3-D) alginate beads in the presence or absence of PGE 2 and analyzed for proteoglycan accumulation and synthesis ( Figure 1B ). In our initial studies (data not shown), Ͼ100 nM PGE 2 significantly decreased (P Ͻ 0.05) the amount of proteoglycan accumulation per cell without noticeable changes in cellular proliferation and survival. Therefore, PGE 2 was used at a concentration of 1 M in subsequent in vitro studies to maximize the biologic effect ( Figure 1B , top). Further, to determine whether the reduction in proteoglycan accumulation was mediated by PGE 2 -dependent inhibition of synthesis, the incorporation of 35 S-sulfate by articular chondrocytes into proteoglycans was quantified. Proteoglycan synthesis was indeed suppressed in the presence of PGE 2 ( Figure 1B, bottom) , suggesting that PGE 2 contributes to imbalanced cartilage homeostasis.
Using real-time RT-PCR, we investigated whether PGE 2 suppresses aggrecan gene expression ( Figure 1C ) and/or increases matrix-degrading enzyme expression ( Figure 1D ), thereby accelerating proteoglycan depletion. IL-1 and bFGF were used in parallel as catabolic experimental controls (5). Compared with untreated (control) chondrocytes, treatment of chondrocytes with 1 M PGE 2 significantly decreased the aggrecan mRNA level by 60% ( Figure 1C ), and this suppression was similar to that seen after treatment with IL-1 and bFGF. Surprisingly, the presence of PGE 2 failed to up-regulate matrix-degrading enzymes, including MMP-1, MMP-3, MMP-13, MMP-14, ADAMTS-4, and ADAMTS-5 (29) (Figure 1D ), while stimulation with both bFGF (100 ng/ml) and IL-1 (10 ng/ml), which are well-known stimulators of cartilage-degrading enzyme expression (5,6), significantly increased expression of these genes. Taken together, these results demonstrate that PGE 2 inhibits proteoglycan production mainly by down-regulating the expression of matrix components (e.g., aggrecan), with minimal effects on the expression of cartilage-degrading enzymes.
Expression of EP receptors in human adult articular cartilage. To identify which of the 4 EP receptors are expressed in normal human articular cartilage, we performed real-time RT-PCR experiments using total RNA extracted from grade-matched (0 or 1) and agematched (25-40 years) knee and ankle articular cartilage. The EP2 and EP4 receptors were most prominently expressed in both knee and ankle cartilage (Figure 2A) , and knee cartilage expressed strikingly higher mRNA levels of the EP2 and EP4 receptors compared with ankle cartilage. Based on these findings, we investigated the pathogenic links of EP2 and EP4 receptors in the progression of OA by monitoring their expression patterns in progressively degenerated (grades 0/1, 2, and 3) or OA cartilage ( Figure 2B ). Age-matched (25-40 years) ankle cartilage (grades 0/1, 2, and 3) and knee cartilage (grade 1 and OA) were analyzed by real-time RT-PCR. In ankle cartilage, grade 2 tissue exhibited a Ͼ2-fold increase in the basal expression of EP2 and EP4 recep- tors compared with grade 0/1 cartilage, and this induction was grade dependent, since grade 3 cartilage exhibited a Ͼ10-fold increase in both EP2 and EP4 receptor expression compared with control ( Figure 2B, top) . Similar grade-dependent results were obtained using knee cartilage (Figure 2B, bottom) . Western blot analysis ( Figure 2C ) corroborated these observations, revealing increased EP2 and EP4 receptor protein expression in OA compared with grade 0/1 knee cartilage.
The biologic effects of PGE 2 are mediated by activation of the EP2 receptor. In arthritic joints (both in OA and in RA), expression of catabolic factors such as PGE 2 (see Figure 1A) , bFGF (4), and IL-1 (30) is significantly increased. Therefore, we determined which of the 4 EP receptors were most responsive to these exogenous stimuli in human articular chondrocytes. Cells (grade 1) from the knee in monolayer were challenged with PGE 2 (1 M), bFGF (100 ng/ml), or IL-1 (10 ng/ml) for 24 hours, and the stimulatory effects on expression of EP receptors were analyzed by real-time RT-PCR ( Figure 3A) . The EP2 and EP4 receptors were the most responsive to all exogenous catabolic stimuli. More specifically, the presence of PGE 2 , bFGF, and IL-1 stimulated EP2 receptor expression 2-, 3.5-, and 4.8-fold, respectively, while EP4 receptor expression was increased 3-, 5-, and 3-fold, respectively, compared with untreated controls. In contrast, changes in the expression of the EP1 or EP3 receptor were negligible.
Based on these observations, we further analyzed the contribution of the EP2 receptor to proteoglycan accumulation ( Figure 3B ), aggrecan gene expression ( Figure 3C ), and collagen production ( Figure 3D ). Human adult articular chondrocytes encapsulated in 3-D alginate beads were cultured for 21 days in the presence or absence of Butaprost (an EP2 receptor-specific agonist), Sulprostone (an EP3 receptor-specific agonist), or IL-1 (positive control). Treatment of cells with Butaprost (1 M) significantly decreased (P Ͻ 0.05) the amount of proteoglycan accumulation per cell without a noticeable change in cellular proliferation and survival (data not shown), and this suppressive effect was similar to that seen after stimulation with PGE 2 and IL-1 ( Figure 3B ). In contrast, activation of EP3 receptor by Sulprostone had no significant effect on proteoglycan accumulation. Further, real-time RT-PCR results demonstrated that treatment of chondrocytes with Butaprost led to a dose-dependent decrease in aggrecan gene expression ( Figure 3C ). Together, these results suggest that the PGE 2 -mediated suppression of proteoglycan production and aggrecan gene expression occurs via the EP2 receptor, and this receptor may be an important initiator of the PGE 2 signaling pathway in human articular cartilage.
The ratio of type II collagen to type I collagen is an important factor for the proper function of mature articular cartilage. In this study, we investigated whether PGE 2 and activation of EP receptors have a biologic influence on modulating this ratio. Our real-time RT-PCR results showed that both PGE 2 and Butaprost decreased levels of type I collagen and type II collagen (data not shown) compared with untreated controls. Interestingly, the ratio of expression of type II collagen to type I collagen was decreased by Butaprost and to a lesser extent by PGE 2 ( Figure 3D ), suggesting a dual role for PGE 2 activation of the EP2 receptor suppression of proteoglycan synthesis/production coupled with a decrease in the type II collagen:type I collagen ratio.
Synergistic effect of the combination of PGE 2 and IL-1 on expression of IL-6 and inducible nitric oxide synthase (iNOS). Both NO and IL-6 are known to play an important role in cartilage metabolism and may mediate pain signaling (31) (32) (33) . We therefore examined the relationship between PGE 2 , IL-6, and iNOS, a gene responsible for the production of NO, in human articular chondrocytes (grade 1) from the knee. After costimulation with PGE 2 and IL-1, the induction of IL-6 mRNA levels was dramatic, showing synergistic up-regulation by a factor of 33 compared with untreated control chondrocytes, significantly higher than that with stimulation with either factor alone ( Figure 4A ). Synergistic augmentation of iNOS was also observed when cells were stimulated with a combination of PGE 2 and IL-1, despite a modest reduction in iNOS mRNA expression after treatment with PGE 2 alone ( Figure 4B) . These striking results demonstrate a robust biologic correlation between PGE 2 and the pain mediators IL-6 and NO that may reflect regulatory interplay between PGE 2 and pain pathways in articular cartilage. PGE 2 suppresses the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway via the EP2 receptor. To characterize the intracellular signaling pathways that modulate proteoglycan expression in response to PGE 2 , we determined the effects of PGE 2 on Akt phosphorylation at serine residue 473, since stimulation of the PI 3-kinase/Akt pathway is required for production of proteoglycan by chondrocytes in response to IGF-1. When given exogenous PGE 2 , various cell types have different effects on the PI 3-kinase/Akt pathway through either an up-regulation (34, 35) or a down-regulation (36,37) of Akt phosphorylation. Thus, we explored whether the PGE 2 -mediated proteoglycan loss was associated with inhibition of the PI 3-kinase/Akt pathway and, if so, whether the EP2 receptor was responsible for the biologic consequences.
Our Western blot results showed that PGE 2 inhibited Akt phosphorylation in Ͻ5 minutes without affecting total Akt levels ( Figure 5A ). Stimulation of the EP2 receptor (with Butaprost), but not the EP3 receptor (with Sulprostone), also decreased phosphorylation of the Akt pathway ( Figure 5B ). A combination of PGE 2 with an EP1/2 antagonist, but not with an EP1 antagonist or an EP4 antagonist, rescued the PGE 2 -induced suppression of the Akt pathway ( Figure 5B ). Further, coincubation of cells with PGE 2 in the presence of IGF-1 revealed that PGE 2 inhibited not only basal levels of Akt, but also the IGF-1-activated Akt pathway which is required for chondrocytic anabolism by IGF-1 (38) . This PGE 2 -mediated attenuation of the IGF-1-induced Akt pathway was dose dependent ( Figure 5C ). Collectively, these results suggest that PGE 2 -mediated suppression of the PI 3-kinase/Akt pathway occurs via the EP2 receptor and may play a role in the suppression of proteoglycan production.
DISCUSSION
This study reveals a significant correlation between arthritic joint diseases and PGE 2 -responsive signaling pathways in human articular cartilage. We demonstrated that PGE 2 functions antianabolically in articular cartilage by suppressing aggrecan synthesis and total proteoglycan accumulation, while only minimally stimulating the expression of cartilage-degrading enzymes (MMPs, ADAMTS). Equally important, this study provides the first evidence that the EP2 receptor is a major mediator of PGE 2 -induced suppression of proteoglycan accumulation in human adult articular chondrocytes. Signaling through the EP2 receptor also decreased the type II collagen:type I collagen ratio to render the ECM less chondrocytic and more fibroblast-like. Furthermore, PGE 2 suppressed PI 3-kinase/Akt signaling via the EP2 receptor, which may be associated with PGE 2 -dependent suppression of aggrecan expression. We also provide support for the novel mechanistic concept that PGE 2 may modulate pain generation in arthritic joints by up-regulating IL-6 and iNOS expression in human articular cartilage.
The biologic activities of PGE 2 in articular cartilage have sparked controversy over its precise role in matrix metabolism. Depending on the experimental system tested and the receptors utilized, PGE 2 has been found to exert both anabolic and catabolic effects on articular cartilage. For example, PGE 2 was shown to exert chondroprotective effects in resting zone chondrocytes (13), human synovial fibroblasts (22) , and at low concentrations in human OA explants (39) and has been found to down-regulate matrix-degrading enzymes (MMP-1) in human chondrocytes (40) . In contrast, other studies suggest that PGE 2 elicits a major catabolic response that perturbs cartilage homeostasis (10, 15, 16) . During inflammatory states, elevated production of PGE 2 causes cartilage resorption by decreasing cellular proliferation, inhibiting aggrecan synthesis, and potentiating the effects of other inflammatory factors, such as IL-1 (9, 16, 41) . PGE 2 has also been correlated with increased MMP production in various tissues, including human articular chondrocytes (42) and OA cartilage explants (43) .
The results from our study suggest an antianabolic role of PGE 2 in human adult articular chondrocytes in vitro via down-regulation of aggrecan gene expression and proteoglycan accumulation and synthesis, which support the findings of Hardy and colleagues, who reported that PGE 2 production from human synovial tissue corresponds to decreased proteoglycan accumulation (15) . In addition, we suggest that PGE 2 does not modulate the expression of representative cartilagedegrading enzymes (e.g., MMPs 1, 3, 13, and 14 as well as ADAMTS-4 and ADAMTS-5) and that, instead, it exerts its effects primarily by inhibiting aggrecan biosynthesis.
The actions of PGE 2 depend on the expression of several distinct EP receptor subtypes on the cell surface, eliciting either catabolic or anabolic effects on cartilage homeostasis (44) . EP1 receptors have been found to increase differentiation in growth plate chondrocytes (45) , while EP2 and EP4 receptors have been associated with both anabolic and catabolic effects in cartilage (44, 46) . Aoyama and colleagues reported that EP2 and EP3 are highly expressed in human and mouse articular chondrocytes, and PGE 2 signals through EP2 to promote cell growth (14) . However, based on our results, we conclude that EP2 and EP4, rather than EP3, are most abundantly expressed in human articular cartilage. This difference may perhaps be attributed to age variations between cartilage samples, since we used adult cartilage samples from normal and degenerative articular cartilage, while Aoyoma and colleagues studied normal cartilage from 4 individuals of various ages (6, 10, 39, and 69 years). Thus, while EP2 and EP4 were highly expressed in our cartilage samples, EP3 was only minimally expressed but may be more prevalent in cartilage of a younger age.
Another intriguing finding of our study is that the EP2 receptor plays a pivotal biologic role in articular cartilage homeostasis. EP2, which functions in an autocrine and/or paracrine manner, transduces the PGE 2 signal to suppress aggrecan expression in human articular chondrocytes. In addition, this receptor is involved in the PGE 2 -mediated decrease in the type II collagen: type I collagen ratio in human cartilage. During the progression of OA in arthritic tissues, a decrease in this ratio is linked to perturbations in cartilage homeostasis (47) , indicating a pathogenic role for ECM replacement through type I collagen. This idea is consistent with findings suggesting that bFGF stimulates cell proliferation in cartilage tissue and decreases the type II collagen:type I collagen expression ratio (Im HJ: unpublished data). Replacement of type II collagen by type I collagen may lead to the formation of fibrocartilage rather than the stronger, more durable hyaline cartilage of a healthy joint. Our current results indicate that inhibition of PGE 2 /EP2 receptor signaling may be beneficial for therapy by antagonizing the suppression of aggrecan production and avoiding collagen substitution, thereby preserving stronger hyaline cartilage and mitigating its degeneration.
Our data reveal striking differences in both basal and PGE 2 -induced expression of the EP2 and EP4 receptors between knee and ankle cartilage (age and grade matched). Because of the longstanding clinical observations that some joints (e.g., knee) are more susceptible to OA than others (e.g., ankle) (1) and that EP2 and EP4 are more abundant in the knee than in the ankle, we suggest that the PGE 2 /EP2 and/or PGE 2 /EP4 signaling pathways may be clinically involved in the onset and progression of OA. Further, we suggest that the catabolic activity of PGE 2 in articular cartilage may be biologically linked to pain symptoms associated with OA in human joints. Pain pathways have been linked to increased levels of IL-6 and NO in mammalian knee joints (32, 33) . Indeed, our studies show that the expression of both IL-6 and iNOS is synergistically increased by PGE 2 and IL-1. Thus, our results indicate that PGE 2 may participate in the generation of pain symptoms in human OA via activation of its cognate EP2 and EP4 receptors, leading to up-regulation of both IL-6 and iNOS.
We have also shown that stimulation of human articular chondrocytes with PGE 2 suppresses Akt phosphorylation, which may be associated with decreased proteoglycan accumulation (38) . Our data provide the first experimental evidence that exogenous PGE 2 inhibits the phosphorylation of Akt via the EP2 receptor in human articular chondrocytes. Taken together with the findings of Starkman and colleagues (38), we suggest that PGE 2 -mediated activation of the EP2 receptor blocks Akt phosphorylation and subsequently suppresses proteoglycan synthesis. This inhibition can be effectively reversed by an EP2 antagonist, revealing the potential use of EP2 antagonists in the prevention of proteoglycan depletion found in arthritic cartilage.
One important limitation of this study must be taken into account. The present study used concentrations of PGE 2 in the micromolar range, and these concentrations are considerably higher than those found in endogenous samples in vivo (nanomolar range). For example, the endogenous range of PGE 2 concentrations in synovial fluid measured in previous studies by ELISA varies from 10 pg/ml to 700 pg/ml (ϳ20 nM) (48, 49) . However, for in vitro studies, we and others (35, 40) used PGE 2 concentrations significantly higher than the reported physiologic concentrations. These differences suggest that the currently available in vitro cell culture experimental models for OA apparently cannot yet faithfully recapitulate biologic responses with physiologic doses of agents detected in synovial fluid. Several parameters may contribute to the necessity to use agents in vitro in excess of their physiologic concentrations in vivo. For example, like cytokines and growth factors, PGE 2 operates in concert with other factors to exert its biologic effects, and absence of these factors in vitro may diminish its efficacy. Alternatively, the effects of PGE 2 may be masked in vitro by secreted inhibitory components that accumulate in the culture media. It is also possible that the specific activity of the exogenously administered PGE 2 is less than that of the same compound present endogenously in synovial fluid. Regardless of these possibilities, however, the concentration used in the current studies yielded informative results and permitted meaningful interpretations that increase our understanding of the biologic effect of PGE 2 and its cognate EP receptors in both in vitro and ex vivo cell culture systems. In summary, we have defined the role of PGE 2 as a potent antianabolic factor at a dose of 1 M in human adult articular cartilage via the suppression of proteoglycan synthesis and aggrecan gene expression. EP2 and EP4 are the predominantly expressed receptors in human articular chondrocytes and appear to be responsive to exogenous stimuli, such as PGE 2 and other catabolic cytokines, suggesting that these receptors may be important signaling initiators of the PGE 2 signaling cascades and may serve as a potential target for therapeutic regimens aimed at preventing progression of arthritis disease in the future. Our findings also provide one plausible mechanism for why certain joints (knees) are more susceptible to OA than others (ankles), since EP2 and EP4 receptors are highly up-regulated in knee cartilage compared with ankle cartilage. We further propose that PGE 2 may mediate pain pathways in articular cartilage via a synergistic stimulatory effect along with the proinflammatory cytokine IL-1 on both IL-6 and iNOS expression. Further investigation should be pursued to help gain a better understanding of the specific signaling cascades governing the complex interactions between PGE 2 and EP receptors in human articular chondrocytes both in vitro and in vivo.
